Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine
Reference10 articles.
1. Lopez-Sendon
J
, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J (2004) 25:1454–1470.
2. Fox
K
. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782–788.
3. Dahlof
B
, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet (2005) 366:895–906. for the ASCOT investigators.
4. Berthet
K
, Neal BC, Chalmers JP, MacMahon SW, Bousser M.-G, Colman SA, Woodward M. Reduction in the risk of recurrent stroke in patients with and without diabetes: the PROGRESS trial. Blood Press (2004) 13:7–13.
5. Cleland
JGF
, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, on behalf of the PEP-CHF investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2005) 26:1369–1378.